Standard Life’s support for the Race for Life bring the company’s ethics and morals into doubt while bringing into question their stance on fraud.
In October last year, Cancer Research UK announced that financial services giant Standard Life would be joining the Race for Life as the events new headline partner.
Given the importance of trust and integrity in financial services, and the need to be vigilant to fraud, in December Race for Life creator Jim Cowan wrote to Andy Curran, Standard Life’s Chief Executive Officer, in order to make him aware of the many issues Cancer Research UK has with trust and integrity, and highlighting the blind eye to employee fraud they continue to show.
Over six weeks later, Jim is still awaiting a reply.
Standard Life claim to be serious about fraud. In 2022 they won they were the ‘Fight Against Fraud’ winner in the UK Customer Service Excellence Awards (aka the Insurance CX Awards). And yet, less than a year later, they are partnering with Cancer Research UK, turning a blind eye to that organisation’s history.
Some might suggest this demonstrates double standards. Others that it displays a lack of integrity. It definitely displays gross hypocrisy.
For over a quarter of a century, Cancer Research UK has been trying to write Jim Cowan from the event’s history. They have told numerous lies in an attempt to rewrite that history and have consistently ignored opportunities to look at evidence and talk to witnesses who support Jim’s truth while offering absolutely no evidence to the contrary. On top of that, they have turned a blind eye to the fraud of former employee Jill MacRae who stole the idea from Jim before later claiming the idea to be her own, building a successful career in the charity sector on the back of that fraud.
We don’t doubt that, at the time of agreeing to support the Race for Life, Standard Life were unaware of any of the above. Cancer Research UK will certainly not have been honest with them.
However, now that they have been made aware, now that they have been offered the opportunity to see the evidence and talk to witnesses, they can no longer claim to be unaware.
Their silence in response to Jim’s letter does not paint them in a very good light. We can only hope that a reply will, eventually, be forthcoming and that Standard Life will do the right thing by either using their position as an event sponsor to put pressure on Cancer Research UK to put right their 29 years of lies, or to withdraw their support for the event on ethical and moral grounds.
For, if a financial services company is happy to look the other way on such matters, what does that say about how much they should be trusted with your savings and investments?
In the Race 4 Truth, Cancer Research UK and Standard Life are lagging behind.